FAKTOR OPTIONSSCHEIN - GENMAB | Market Closed - Boerse Frankfurt Warrants 15:21:03 31/05/2024 BST | ||
| 3.79 EUR | -1.81% |
|
| Current month | -1.04% | ||
| 1 month | -1.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 3.79 | -1.81% |
| 30/05/24 | 3.86 | -1.28% |
| 29/05/24 | 3.91 | +2.62% |
| 28/05/24 | 3.81 | +1.60% |
| 27/05/24 | 3.75 | -4.82% |
Real-time Boerse Frankfurt Warrants
Last update May 31, 2024 at 03:21 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
BNP Paribas
|
| WKN | PN3GES |
| ISIN | DE000PN3GES0 |
| Date issued | 10/11/2021 |
| Strike | 1,931 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.62 € |
|---|---|
| Lowest since issue | 1.49 € |
| Spread | 0.02 € |
| Spread % | 0.52% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,937
DKK
Average target price
2,466
DKK
Spread / Average Target
+27.30%
- Stock Market
- Certificates
- Certificat
